New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADXRadiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
0.63
0.04
−5.97%
After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.
Follow RADX
Alert me
Revenue to profit Fiscal 2026, year to Jun 30, 2026
It lost $38.7M on $1.9M of revenue: $2057.51 for every $100. What is an income statement?
| Revenue | 1.9 | 100.0% |
|---|---|---|
| Cost of revenue | −1.7 | −90.5% |
| Gross profit | 0.2 | 9.5% |
| Research & development | −33.9 | −1805.1% |
| Selling, general & admin | −12.6 | −672.8% |
| Other operating costs | +7.8 | 416.8% |
| Operating income | −38.5 | −2051.5% |
| Other income, net | −0.1 | −4.1% |
| Income tax | 0.0 | −2.0% |
| Net income | −38.7 | −2057.5% |
Net margin (right axis)
| FY24 | FY25 | FY26 | |
|---|---|---|---|
| Revenue | $0.0B | $2.4M | $1.9M |
| Operating income | −$31M | −$25M | −$39M |
| Net income | −$31M | −$25M | −$39M |
| Net margin (right axis) | −16027.0% | −1055.3% | −2057.5% |
| Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|
Revenue |
0.20 | 2.35 | 1.88 |
Revenue Growth |
— | 1,099.29% | (20.16%) |
Cost of Revenue |
— | 2.33 | 1.70 |
Gross Profit |
0.20 | 0.03 | 0.18 |
R&D Expenses |
15.14 | 17.82 | 33.91 |
SG&A Expenses |
10.28 | 10.71 | 12.64 |
Operating Income |
(30.96) | (24.72) | (38.54) |
Non-operating Income/Expense |
(0.42) | (0.04) | (0.08) |
Non-operating Interest Expenses |
0.42 | 0.04 | 0.08 |
| (31.38) | (24.76) | (38.62) | |
Income Tax Provision |
0.06 | 0.07 | 0.04 |
Income after Tax |
(31.44) | (24.83) | (38.65) |
Net Income Common |
(31.44) | (24.83) | (38.65) |
EPS (Basic) |
(24.41) | (3.58) | (3.65) |
EPS (Diluted) |
(24.41) | (3.58) | (3.65) |
Shares (Basic, Weighted) |
1.29 | 6.94 | 10.24 |
Shares (Diluted, Weighted) |
1.29 | 6.94 | 10.24 |
Gross Margin |
100.00% | 1.08% | 9.52% |
EBIT Margin |
(15,779.92%) | (1,050.63%) | (2,051.48%) |
EBT margin |
(15,994.80%) | (1,052.43%) | (2,055.54%) |
Net Profit Margin |
(16,027.01%) | (1,055.27%) | (2,057.51%) |
Free Cash Flow Margin |
(7,679.71%) | (926.07%) | (1,906.94%) |
EBITDA |
(28.91) | (23.04) | (36.70) |
EBIT |
(30.96) | (24.72) | (38.54) |
Income from Continuous Operations |
(31.44) | (24.83) | (38.65) |
Consolidated Net Income/Loss |
(31.44) | (24.83) | (38.65) |
EPS (Basic, from Continuous Ops) |
(24.41) | (3.58) | (3.77) |
EPS (Basic, Consolidated) |
(24.41) | (3.58) | (3.77) |
EPS (Diluted, from Cont. Ops) |
(24.41) | (3.58) | (3.77) |
Shares (Diluted, Average) |
— | 2,178.55 | 10.27 |
EPS (Diluted, Consolidated) |
(24.41) | (3.58) | (3.77) |
EBITDA Margin |
(14,734.96%) | (979.20%) | (1,953.72%) |
Operating Cash Flow Margin |
(7,679.71%) | (1,008.57%) | (1,906.94%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026